Nurix Therapeutics, Inc.
NRIXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of. Valued at $1.83B, NRIX is a small-cap name in its sector. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Market Cap
$1.83B
Beta
1.88
P/E (TTM)
—
P/E (Fwd)
-6.17
EPS (TTM)
$-3.17
EPS (Fwd)
$-2.86
ROE
-61.4%
ROA
-31.5%
Cash
$540.7M
Total Debt
$58.7M
Free CF
-$145.5M
52W Change
66.2%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $540.7M in cash comfortably exceeding the $58.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$145.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -61.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $38.6M (2022) to $84.0M (2025), reflecting a 117% increase over the period.
Nurix Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, NRIX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Nurix Therapeutics, Inc.'s trajectory.